Answers are grounded in this paper and cite their sources.
A long-acting PLGA/Eudragit microsphere formulation was developed to replace frequent oral dosing for Parkinson's disease. It successfully delivered hydrophilic pramipexole, achieving sustained release for up to 18 days with excellent syringeability.
No takes yet. Share an insight, caveat, or question.
Nakmode et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: